Stroke risk and NSAIDs: An australian population-based study

Medical Journal of Australia

Volumn 195, Issue 9, 2011, Pages 525-529

  Caughey, Gillian E ^a   Roughead, Elizabeth E ^a   Pratt, Nicole ^a   Killer, Graeme ^b   Gilbert, Andrew L ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Department of Veterans' Affairs ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR;

AGED; ARTICLE; AUSTRALIA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG UTILIZATION; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; VETERAN; CHEMICALLY INDUCED DISORDER; PREVALENCE; RISK; STROKE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUSTRALIA; BRAIN ISCHEMIA; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; PREVALENCE; RETROSPECTIVE STUDIES; RISK; STROKE;

EID: 84855163593     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja11.10055     Document Type: Article

References (35)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
2. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
3. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080.
4. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
5. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-1308.
6. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342; c7086.
7. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.
8. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-481.
9. Haag MDM, Bos MJ, Hofman A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 2008; 168: 1219-1224.
10. Roumie CL, Mitchel EF Jr, Kaltenbach L, et al. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008; 39: 2037-2045.
11. Fosbol EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010; 3: 395-405.
12. Gislason GH. Use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with increased risk of stroke among healthy people. European Society of Cardiology Congress; 2010 Aug 28-Sep 1; Stockholm, Sweden.
13. Chang CH, Shau WY, Kuo CW, et al. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke 2010; 41: 1884-1890.
14. Caughey GE, Cleland LG, Penglis PS, et al. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001; 167: 2831-2838.
15. Chan CC, Reid CM, Aw TJ, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27: 2332-2341.
16. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
17. Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108: 7-13.
18. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-7568.
19. Australian Government Department of Veterans' Affairs. Treatment population statistics. Quarterly report - June 2010. Canberra: DVA, 2010. http://www.dva.gov.au/aboutDVA/ Statistics/Documents/TpopJun10.pdf (accessed Jun 2011).
20. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical code classification index with defined daily doses. http://www.whocc.no/ atcddd/ (accessed Sep 2011).
21. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits. PBS for health professionals. 2011. http://www.pbs.gov.au/ (accessed Jun 2011).
22. National Centre for Classification in Health. International statistical classification of diseases and related health problems, 10th revision, Australian modification (ICD-10-AM). 7th ed. Sydney: NCCH, 2010.
23. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996; 7: 478-484.
24. Caughey GE, Roughead EE, Pratt N, et al. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf 2010; 19: 977-982.
25. Langton PE, Hankey GJ, Eikelboom JW. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events. Med J Aust 2004; 181: 524-525.
26. Australian Government Department of Health and Ageing. Australian statistics on medicine 2008. Canberra: Commonwealth of Australia, 2009.
27. Caughey GE, Ramsay EN, Vitry AI, et al. Comorbid chronic diseases, discordant impact on mortality in the elderly; a 14 year longitudinal population study. J Epidemiol Community Health 2010; 64: 1036-1042.
28. Corderoy A. Study links Voltaren and Nurofen to strokes. Sydney Morning Herald 2010; 14 Sep.
29. Corderoy A. Painkiller linked to stroke. The Age (Melbourne) 2010; 14 Sep.
30. Rose D. TGA monitoring drugs with stroke risk. MedConnect 2010; 14 Sep.
31. Mangoni AA, Woodman RJ, Gaganis P, et al. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol 2010; 69: 689-700.
32. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009; 2: 155-163.
33. Solomon DH, Avorn J, Stürmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheumatism 2006; 54: 1378-1389.
34. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52: 1628-1636.
35. Australian Institute of Health and Welfare. Health care usage and costs. A comparison of veterans and war widows and widowers with the rest of the community. Canberra: AIHW, 2002. (AIHW Cat. No. PHE 42.)